Sign in
CompletedPhase 4

Helicobacter Pylori and Vonoprazan Dual Therapy

Key facts

Who runs it
The First Affiliated Hospital of Nanchang University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
504 people enrolled
Started
13 Feb 2023
Ended
25 Jan 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • L-VA dual therapy
  • H-VA dual therapy
Record updated
23 August 2024

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Consecutive H. pylori-infected subjects ages from 18 to 70 without eradication history

Who cannot take part

  • proton pump inhibitors and antibiotics use within one month
  • allergy to amoxicillin or vonoprazan
  • acute upper gastrointestinal bleeding, gastric cancer or other tumors, Zollinger-Ellison syndrome, history of gastric surgery
  • serious illness including neurological, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urological, endocrinological or hematological disorders
  • pregnancy or breast feeding
  • not willing to participate in the study

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Our previous study included 119 Helicobacter pylori(H. pylori)-infected Chinese patients without previous eradication history who were randomized to low-or high-dose amoxicillin-vonoprazan regimens consisting of amoxicillin 1 gram either b.i.d. or t.i.d plus vonoprazan 20 mg b.i.d for 7 or 10 days. Neither 7-or 10-day VA dual therapy with either b.i.d. or t.i.d. amoxicillin achieved satisfied efficacy (i.e., <90%) when given as first-line treatment for H. pylori infection. This study evaluated the efficacy and safety of low-and high-dose amoxicillin-vonoprazan dual therapy for 14 days as first-line treatment for H. pylori in China.

The 2 groups in the trial

  • vonoprazan and low-dose amoxicillin dual therapyTreatment being tested

    1000 mg amoxicillin capsules twice daily and 20 mg vonoprazan Fumarate Tablets twice daily for 14 days

    Treatment: L-VA dual therapy

  • vonoprazan and high-dose amoxicillin dual therapyExisting treatment, for comparison

    1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days

    Treatment: H-VA dual therapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Fourteen-day Vonoprazan and Low-or High-dose Amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection: a Prospective, Multi-centers, Open-labeled, Non-inferior, Randomized Clinical Study
Publications
Record updated
23 August 2024